Carmelo Scarpignato, MD, DSc, PharmD, MPH, FRCP, FACP, FCP, FACG, AGAF
Parma, Emilia Ramagna | Italy
Carmelo Scarpignato graduated in Biochemistry at the University of Messina, and in Medicine and Surgery at the University of Modena in Italy. He is currently Professor of Pharmacology & Therapeutics at University of Parma, Medical School and Associate Professor of Gastroenterology at University of Nantes. He is also Consultant Clinical Pharmacologist at Maggiore University Hospital in Parma. He has been Visiting Professor at some prestigious European and USA Universities.
Professor Scarpignato’s main research interests focus on digestive clinical pharmacology, gastrointestinal motility, and upper GI pathophysiology. He has authored 560 publications (of which 330 are full papers or book chapters) on
these topics and has also edited 28 books on clinical evaluation of GI function and on Pharmacology & Therapeutics of Digestive Diseases. He is or has been on the editorial boards of Pharmacology, Gut, Digestion, Digestive Diseases, Current Gastroenterology Reports, Alimentary Pharmacology & Therapeutics, BMC Gastroenterology, BMC Medicine, World Journal of Gastroenterology, American Journal of Pharmacology & Therapeutics, Therapeutic Advances in Drug Safety and Current Clinical Pharmacology, amongst others. He is also a Section Editor (GI and Liver Pharmacology) of Fundamental and Clinical Pharmacology and of Gastroenterology International, and has been co-Editor of two prestigious book series, Frontiers of Gastrointestinal Research and Progress in Basic and Clinical Pharmacology.
Professor Scarpignato is a Fellow of the Royal College of Physicians (London), The American College of Physicians, the American College of Clinical Pharmacology, the American College of Gastroenterology and of the American Gastroenterological Association. In addition, he is a member of several national and international scientific societies, including the British Pharmacological Society and the American Society for Pharmacology and Experimental Therapeutics (ASFET). He is presently the Secretary General of the World Organization for Specialized Studies on Diseases of the Esophagus (OESO) and Governor for Italy of the American College of Gastroenterology (ACG). His biography has been included into the 2009-2010 Edition of Who’s Who in Medicine and Healthcare.
"Microbiota-directed Therapies for Treatment and Prevention of SIBO"
SIBO is a challenging clinical condition. Its etiology is usually complex and multifactorial and the syndrome is often misdiagnosed and generally under-diagnosed. Clinical symptoms may be subtle and non-specific, which makes diagnosis difficult without objective testing.
The availability of poorly absorbed antimicrobials (i.e. rifaximin) as well as effective pro- and prebiotics has been an advance in treatment, which needs to be refined to identify the best dose and duration to maximize eradication and prevent recurrence. Stimulating GI motility will restore the housekeeping intestinal activity and - by this means - SIBO can be treated and its recurrence prevented.
Understand that - since pathophysiology of SIBO is multifactorial - treatment should also be multifactorial
Manage SIBO and related symptoms through modulation of gut microbiota with antibiotics, probiotics and prebiotics
Appreciate that - unless the triggering cause removed - SIBO is a chronic, relapsing condition. As a consequence, treatment should be cyclic
Prevent SIBO recurrence and its dangerous consequences